JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 1
DOI:10.33266/1024-6177-2025-70-1-93-101
V.K. Tishchenko1, O.P. Vlasova1, 2, S.A. Ivanov1,3, A.D. Kaprin2, 3, 4
Radiopharmaceuticals Based on Somatostatin Analogs and Technetium-99m Radionuclide for Diagnosis of Neuroendocrine Tumors: a Literature Review
1 A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Obninsk, Russia
2 National Medical Research Radiological Center, Moscow, Russia
3 Рeoples Friendship University of Russia, Moscow, Russia
4 P.A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Moscow, Russia
Contact person: Viktoriia Konstantinovna Tishchenko, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENTS
Introduction
Somatostatin receptor imaging capabilities
Radiopharmaceuticals based on somatostatin receptors agonists and technetium-99m
Radiopharmaceuticals based on somatostatin receptors antagonists and technetium-99m
Conclusion
Keywords: radiopharmaceuticals, technetium-99m, somatostatin analogs, radionuclide diagnosis, neuroendocrine tumors
For citation: Tishchenko VK, Vlasova OP, Ivanov SA, Kaprin AD. Radiopharmaceuticals Based on Somatostatin Analogs and Technetium-99m Radionuclide for Diagnosis of Neuroendocrine Tumors: a Literature Review. Medical Radiology and Radiation Safety. 2025;70(1):93–101. (In Russian). DOI:10.33266/1024-6177-2025-70-1-93-101
References
1. Панкратова Е.А., Шпрах З.С. Рецепторы к соматостатину: локализация и методы визуализации (обзор литературы) // Российский биотерапевтический журнал. 2022. Т. 21. №1. С. 10–20. [Pankratova Ye.A., Shprakh Z.S. Somatostatin Receptors: Localization and Imagining Methods (Review). Rossiyskiy Bioterapevticheskiy Zhurnal = Russian Journal of Biotherapy. 2022;21;1:10-20 (In Russ.)]. DOI: 10.17650/1726-9784- 2022-21-1-10-20.
2. Milewska-Kranc A., Cwikla J.B., Kolasinska-Cwikla A. The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors. Cancers (Basel). 2023;16;1:116. doi: 10.3390/cancers16010116.
3. Nock BA., Kanellopoulos P., Joosten L., Mansi R., Maina T. Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists. Pharmaceuticals (Basel). 2023;16;5:674. doi: 10.3390/ph16050674.
4. Levine R., Krenning E.P. Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. J. Nucl. Med. 2017;58;S2:3S-9S. doi: 10.2967/jnumed.116.186502.
5. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hagen M., Postema P.T., de Jong M., Reubi J.C., Visser T.J., Reijs A.E.M., Hofland L.J., Koper J.W., Lamberts S.W.J. Somatostatin Receptor Scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-Octreotide: the Rotterdam Experience with more than 1000 Patients. Eur J Nucl Med. 1993;20;8:716–731. doi: 10.2967/jnumed.116.186502.
6. Слащук К.Ю., Румянцев П.О., Дегтярев М.В., Серженко С.С., Баранова О.Д., Трухин А.А., Сирота Я.И. Молекулярная визуализация нейроэндокринных опухолей при соматостатин-рецепторной сцинтиграфии (ОФЭКТ/КТ) с 99mTc-тектротидом // Медицинская радиология и радиационная безопасность. 2020. Т.65. №2. С. 44-49. [Slashchuk K.Yu., Rumyantsev P.O., Degtyarev M.V., Serzhenko S.S., Baranova O.D., Trukhin A.A., Sirota Ya.I. Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2020;65;2:44-9 (In Russ.)]. DOI: 10.12737/1024-6177-2020-65-2-44-49.
7. Рабинович Э.З., Савченко А.Ю., Сухов В.Ю., Перелыгин В.В. Аспекты проблемы проведении клинических исследований современных таргетных радиофармацевтических препаратов // Формулы Фармации. 2022. № 4(3). С. 27-42. [Rabinovich E.Z., Savchenko A.Yu., Sukhov V.Yu., Perelygin V.V. Aspects of the Problem of Clinical Trials of Modern Targeted Radiopharmaceuticals. Formuly Farmatsii = Pharmacy Formulas. 2022;4;3;27-42 (In Russ.)]. DOI: 10.17816/phf239422.
8. Boschi A., Uccelli L., Martini P. A Picture of Modern Tc-99m Radiopharmaceuticals: Production, Chemistry, and Applications in Molecular Imaging. Appl Sci. 2019;9;12:2526. https://doi.org/10.3390/app9122526.
9. Shi J., Liu S. Clinical Application of 99mTc-Labeled Peptides for Tumor Imaging: Current Status and Future Directions. iRADIOLOGY. 2024;2;1:17-34. DOI: 10.1002/ird3.55.
10. Eychenne R., Bouvry C., Bourgeois M., Loyer P., Benoist E., Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules. 2020;25:4012. doi: 10.3390/molecules25174012.
11. Makris G., Kuchuk M., Gallazzi F., Jurisson S.S., Smith C.J., Hennkens H.M. Somatostatin Receptor Targeting with Hydrophilic [99mTc/186Re]Tc/Re-tricarbonyl Nodaga and Nota Complexes. Nucl Med Biol. 2019;71:39-46. https://doi.org/10.1016/j.nucmedbio.2019.04.004.
12. Ларькина М.С., Подрезова Е.В., Брагина О.Д., Тагирова Е.А., Чернов В.И., Юсубов М.С., Нестеров Е.А., Скуридин В.С., Кривощеков С.В., Яновская Е.А., Гурто Р.В., Белоусов М.В. Разработка способа получения производного октреотида для диагностики нейроэндокринных опухолей // Бюллетень сибирской медицины. 2019. Т. 18. №3. С. 72-80. https://doi.org: 10.20538/1682-0363-2019-3-72–80. [Lar’kina M.S., Podrezova Ye.V., Bragina O.D., Tagirova Ye.A., Chernov V.I., Yusubov M.S., Nesterov Ye.A., Skuridin V.S., Krivoshchekov S.V., Yanovskaya Ye.A., Gurto R.V., Belousov M.V. Development of a Method for Preparing Octreotide Derivative for Diagnosis of Neuroendocrine Tumors. Byulleten’ Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2019;18;3:72-80 (In Russ.)]. https://doi.org/10.20538/1682-0363-2019-3-72-80.
13. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Mäcke H.R. Affinity Profiles for Human Somatostatin Receptor Subtypes SST1–SST5 for Somatostatin Radiotracers Selected for Scintigraphic and Radiotherapeutic Use. Eur J Nucl Med. 2000;27;3:273-82. doi: 10.1007/s002590050034.
14. Virgolini I., Leimer M., Handmaker H., Lastoria S., Bischof C., Muto P., Pangerl T., Gludovacz D., Peck-Radosavljevic M., Lister-James J., Hamilton G., Kaserer K., Valent P., Dean R. Somatostatin Receptor Subtype Specificity and in Vivo Binding of a Novel Tumor Tracer, 99mTc-P829. Cancer Res. 1998;58;9:1850-1859.
15. URL: https://www.rxlist.com/neotect-drug.htm#description. (accessed 15 August 2024).
16. Lebtahi R., Le Cloirec J., Houzard C., Daou D., Sobhani I., Sassolas G., Mignon M., Bourguet P., Le Guludec D. Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy. J Nucl Med. 2002;43;7:889-895.
17. Maina T., Nock B., Nikolopoulou A., Sotiriou P., Loudos G., Maintas D., Cordopatis P., Chiotellis E. [99mTc] Demotate, a New 99mTc-Based [Tyr3] Octreotate Analogue for the Detection of Somatostatin Receptor-Positive Tumours: Synthesis and Preclinical Results. Eur J Nucl Med Mol Imag. 2002;29;6:742-53. doi: 10.1007/s00259-002-0782-9.
18. Decristoforo C., Maina T., Nock B., Gabriel M., Cordopatis P., Moncayo R. 99mTc-Demotate 1: First Data in Tumour Patients-Results of a Pilot/Phase I Study. Eur J Nucl Med Mol Imaging. 2003;30;9:1211-1219. doi: 10.1007/s00259-003-1225-y.
19. Maina T., Nock B.A., Cordopatis P., Bernard B.F., Breeman W.A.P, van Gameren A., van der Berg R., Reubi J.C., Krenning E.P., de Jong M. [99mTc] Demotate 2 in the Detection of Sst(2)-Positive Tumours: a Preclinical Comparison with [111In]DOTA-tate. Eur J Nucl Med Mol Imaging 2006;33(7):831-840. doi: 10.1007/s00259-006-0068-8.
20. Kaihani S., Sadeghzadeh N. Study of the 99mTc-Labeling Conditions of 6-Hydrazinonicotinamide-Conjugated Peptides from a new Perspective: Introduction to the Term Radio-Stoichiometry. J Labelled Comp Radiopharm. 2020;63;14:582-596. https://doi.org/10.1002/jlcr.3883.
21. Meszaros L., Dose A., Biagini S.C.G., Blower P. Hydrazinonicotinic Acid (HYNIC) – Coordination Chemistry and Applications in Radiopharmaceutical Chemistry. Inorg Chim Acta. 2020;363;6:1059-1069. https://doi.org/10.1016/j.ica.2010.01.009.
22. Decristoforo C., Melendez-Alafort L., Sosabowski J.K., Mather S.J. 99mTc-HYNIC-[Tyr3]-Octreotide for Imaging Somatostatin-Receptor-Positive Tumors: Preclinical Evaluation and Comparison with 111In-Octreotide. J Nucl Med. 2000;41;6:1114-1119.
23. URL: https://mdcr.ru/tektrotyd (accessed 16 July 2024).
24. Garai I., Barna S., Nagy G., Forgacs A. Limitations and Pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) Scintigraphy. Nucl Med Rev Cent East Eur. 2016;19;2:93-98. doi: 10.5603/NMR.2016.0019.
25. Trogrlic M., Tezak S. 99mTc-EDDA/HYNIC-TOC in Management of Patients with Head and Neck Somatostatin Receptor Positive Tumors. Nucl Med Rev Cent East Eur. 2016;19;2:74-80. doi: 10.5603/NMR.2016.0016.
26. Briganti V., Cuccurullo V., Berti V., Di Stasio G.D., Linguanti F., Mungai F., Mansi L. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases). Curr Radiopharm. 2020;13;3:166-176. doi: 10.2174/1874471013666191230143610.
27. Artiko V., Afgan A., Petrović J., Radović B., Petrović N., Vlajković M., Šobić-Šaranović D., Obradović V. Evaluation of Neuroendocrine Tumors with 99mTc-EDDA/HYNIC TOC. Nucl Med Rev Cent East Eur. 2016;19;2:99-103. doi: 10.5603/NMR.2016.0020.
28. Sergieva S., Robev B., Dimcheva M., Fakirova A., Hristoskova R. Clinical Application of SPECT-CT with 99mTc-Tektrotyd in Bronchial and Thymic Neuroendocrine Tumors (NETs). Nucl Med Rev Cent East Eur. 2016;19;2:81-7. doi: 10.5603/NMR.2016.0017.
29. Boutsikou E., Porpodis K., Chatzipavlidou V., Hardavella G., Gerasimou G., Domvri K., Papadopoulos N., Avramidou V., Spyratos D., Kontakiotis T., Zarogoulidis K. Predictive Value of 99mTc-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis. Technol. Cancer Res. Treat. 2019;18:15330338119842586. doi: 10.1177/1533033819842586.
30. Gherghe M., Lazăr A.M., Stanciu A.E., Mutuleanu M.D., Sterea M.C., Petroiu C., Gale LN. The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs? Cancers (Basel). 2022;14;11:2725. doi: 10.3390/cancers14112725.
31. Юкина М.Ю., Трошина Е.А., Нуралиева Н.Ф., Дегтярев М.В., Мокрышева Н.Г. ОФЭКТ/КТ с 99mTc-Тектротидом в диагностике инсулиномы // Ожирение и метаболизм. 2023. Т.20. №1. С. 43-48. [Yukina M.Yu., Troshina Ye.A., Nuralieva N.F., Degtyarev M.V., Mokrysheva N.G. SPECT/CT with 99mTc-Tectrotide in the Diagnosis of Insulinoma. Ozhireniye i Metabolism = Obesity and metabolism. 2023;20(1):43-48. (In Russ.)]. https://doi.org/10.14341/omet12977.
32. Moriguchi-Jeckel C.M., Madke R.R., Radaelli G., Viana A., Nabinger P., Fernandes B., Gössling G., Berdichevski E.H., Vilas E., Giacomazi J., Rocha M.S., Borges J.A., Hoffmann E., Greggio S., Venturin G.T., Barris C.H., Zaffaroni F., Werutsky G., da Costa J.C. Clinical Validation and Diagnostic Accuracy of 99mTc-EDDA/HYNIC-TOC Compared to 111In-DTPA-octreotide in Patients with Neuroendocrine Tumours: the LACOG 0214 study. Ecancermedicalscience. 2023;17:1582. doi: 10.3332/ecancer.2023.1582.
33. Liepe K., Becker A. 99mTc-Hynic-TOC Imaging in the Diagnostic of Neuroendocrine Tumors. World J Nucl Med. 2018;17;3:151-156. doi: 10.4103/wjnm.WJNM_41_17.
34. Chen L., Li F., Zhuang H., Jing H., Du Y., Zeng Z. 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma. J Nucl Med. 2009;50:397-400. doi: 10.2967/jnumed.108.058693.
35. Hubalewska-Dydejczyk A., Fröss-Baron K., Mikołajczak R., Maecke H.R., Huszno B., Pach D., Sowa-Staszczak A., Janota B., Szybiński P., Kulig J. 99mTc EDDA/HYNIC Octreotate Scintigraphy, an Efficient Method for the Detection and Staging of Carcinoid Tumors: Results of 3 years’ Experience. Eur J Nucl Med Mol Imaging. 2006;33;10:1123-1133. doi: 10.1007/s00259-006-0113-7.
36. Sager S., Kabasakal L., Halac M., Maecke H., Uslu L., Önsel Ç., Kanmaz B. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE Octreotide Scintigraphy with FDG PET and 99mTc-MIBI in Local Recurrent or Distant Metastatic Thyroid Cancers. Clin Nucl Med. 2013;38;5:321-5. doi: 10.1097/RLU.0b013e3182868062.
37. Deveci E.K., Ocak M., Bozkurt M.F., Türker S., Kabaskal L., Ugur O. The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours. Mol Imaging Radionucl Ther. 2013;22;3:76-84. doi: 10.4274/Mirt.68552.
38. Korde A., Mallia M., Shinto A., Sarma H.D., Samuel G., Banerjee S. Improved Kit Formulation for Preparation of 99mTc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors. Cancer Biother Radiopharm. 2014;29;9:387-94. doi: 10.1089/cbr.2014.1657.
39. Mukherjee A., Korde A., Shinto A., Sarma H.D., Kamaleswaran K., Dash A. Studies on Batch Formulation of a Freeze Dried Kit for the Preparation of 99mTc-HYNIC-TATE for Imaging Neuroendocrine Tumors. Appl Radiat Isot. 2019;145:180-186. doi: 10.1016/j.apradiso.2018.12.027.
40. Behera A., Banerjee I., De K., Chattopadhyay S., Misra M. Synthesis, Radiolabelling and Biological Evaluation of new Somatostatin Receptor Positive Tumour Imaging Agent. Amino Acids. 2011. DOI 10.1007/s00726-012-1423-7.
41. De K., Bhowmik A., Behera A., Banerjee I., Ghosh M.K., Misra M. Synthesis, Radiolabeling, and Preclinical Evaluation of a new Octreotide Analog for Somatostatin Receptor-Positive Tumor Scintigraphy. J Pept Sci. 2012;18:720. https://doi.org/10.1002/psc.2458.
42. Gandomkar M., Najafi R., Shafiei M., Mazidi M., Ebrahimi S.E.S. Preclinical Evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-Octreotide as a New Analogue in the Detection of Somatostatin-Receptor-Positive Tumors. Nucl Med Biol. 2007;34;6:651-657. doi: 10.1016/j.nucmedbio.2007.06.006.
43. Nikolopoulou A., Nock B.A., Maina T. 99mTc Targeting of Sst2-Expressing Tumors by Tetraamineoctreotide: First Results in CA20948 Cells and Rat Models. Anticancer Res. 2006;26;1A:363-366.
44. Gandomkar M., Najafi R., Babaei M.H., Shafiei M., Ebrahimi S.E.S. Synthesis, Development and Preclinical Comparison of Two New Peptide Based Freeze-Dried Kit Formulation 99mTc-EDDA-Tricine-HYNIC-TOC and 99mTc-EDDA-Tricine-HYNIC-TATE for Somatostatin Receptor Positive Tumor Scintigraphy. DARU. 2006;14;4:183-189.
45. Storch D., Béhé M., Walter M.A., Chen J., Powell P., Mikolajczak R., Mäcke H.R. Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3,Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization? J Nucl Med. 2005;46:1561-1569.
46. Dong C., Zhao H., Yang S., Shi J., Huang J., Cui L., Zhong L., Jin X., Li F., Liu Z., Jia B. 99mTc-Labeled Dimeric Octreotide Peptide: A Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors. Mol Pharm. 2013;10:2925. https://pubs.acs.org/doi/10.1021/mp400040z.
47. De K., Banerjee I., Misra M. Radiolabeled New Somatostatin Analogs Conjugated to DOMA Chelator Used as Targeted Tumor Imaging Agent: Synthesis and Radiobiological Evaluation. Amino Acids. 2015;47:1135-1153. DOI 10.1007/s00726-015-1942-0.
48. Fani M., Mansi R., Nicolas G.P., Wild D. Radiolabeled Somatostatin Analogs – A Continuously Evolving Class of Radiopharmaceuticals. Cancers. 2022;14:1172. doi: 10.3390/cancers14051172.
49. Radford L., Gallazzi F., Watkinson L., Carmack T., Berendzen A., Lewis M.R., Jurisson S.S., Papagiannopoulou D., Hennkens H.M. Synthesis and Evaluation of a 99mTc Tricarbonyl-Labeled Somatostatin Receptor-Targeting Antagonist Peptide for Imaging of Neuroendocrine Tumors. Nucl Med Biol. 2017;47:4-9. doi: 10.1016/j.nucmedbio.2016.12.002.
50. Radford L.L., Papagiannopoulou D., Gallazzi F., Berendzen A., Watkinson L., Carmack T., Lewis M.R., Jurisson S.S., Hennkens H.M. Synthesis and Evaluation of Re/99mTc(I) Complexes Bearing a Somatostatin Receptor-Targeting Antagonist and Labeled Via a Novel [N,S,O] Clickable Bifunctional Chelating Agent. Bioorg Med Chem. 2019;27;3:492-501. doi: 10.1016/j.bmc.2018.12.028.
51. Gaonkar R.H., Wiesmann F., Pozo L.D., McDougall L., Zanger S., Mikolajczak R., Mansi R., Fani M. SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. Pharmaceuticals. 2021;14:300. doi: 10.3390/ph14040300.
52. Fani M., Weingaertner V., Peitl P.K., Mansi R., Gaonkar R., Garnuszek P., Mikolajczak R., Novak D., Simoncic U., Hubalewska-Dydejczyk A., Rangger C., Kaeopookum P., Decristoforo C. Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals (Basel). 2020;14;1:19. doi: 10.3390/ph14010019.
53. Novak D., Janota B., Hörmenn A.A., Sawicka A., Kroselj M., Hubalewska-Dydejczyk A., Fani M., Mikolajczak R., Kolenc P., Decristoforo C., Garnuszek P. Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 2023;15;3:885. doi: 10.3390/pharmaceutics15030885.
54. Opalinska M., Ležaić L., Decristoforo C., Kolenc P., Mikolajczak R., Studen A., Simoncic U., Virgolini I., Trofimiuk-Muldner M., Garnuszek P., Rangger C., Fani M., Glowa B., Skorkiewicz K., Hubalewska-Dydejczyk A. Comparison of 99mTc Radiolabeled Somatostatin Antagonist with [68Ga]Ga-DOTA-TATE in a Patient with Advanced Neuroendocrine Tumor. Eur J Nucl Med Mol Imaging. 2023;50:4110-4111. doi: 10.1007/s00259-023-06335-9.
55. Hubalewska-Dydejczyk A., Ležaić L., Decristoforo C., Mikolajczak R., Virgolini I., Kolenc P., Studen A., Simoncic U., Opalinska M., Trofimiuk-Muldner M., Garnuszek P., di Santo G., 56. Novak D., Rangger C., Kroselj M., Skorkiewicz K., Fani M., Janota B., Glowa B., Sawicka A. How Close We are to Optimise the Assessment of SSTR Status in NEN with a Radiolabelled SSTR Antagonist-Final Results of the TECANT Clinical Trial: Novel 99mTc-labelled Somatostatin Antagonists in the Diagnostic Algorithm of Neuroendocrine Neoplasms. Endocrine Abstracts. 2024;99:OC7.3. doi: 10.1530/endoabs.99.OC7.3.
56. Abiraj K., Ursillo S., Tamma M.L., Rylova S.N., Waser B., Constable E.C., Fani M., Nicolas G.P., Reubi J.C., Maecke H.R. The Tetraamine Chelator Outperforms HYNIC in a New Technetium-99m-Labelled Somatostatin Receptor 2 Antagonist. EJNMMI Research. 2018;8:75. https://doi.org/10.1186/s13550-018-0428-y.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The research was carried out with the financial support of Ministry of Health of the Russian Federation within implementation of state assignment № 124030500022-1.
Contribution. S.A. Ivanov, A.D. Kaprin aided in the concept and plan of the study; V.K. Tishchenko, O.P. Vlasova provided collection and analysis of data; preparation of the manuscript – V.K. Tishchenko, O.P. Vlasova.
Article received: 20.10.2024. Accepted for publication: 25.11.2024.